RT Journal Article T1 The Role of Statins on Helicobacter pylori Eradication: Results from the European Registry on the Management of H. pylori (Hp-EuReg). A1 Caldas, María A1 Pérez-Aisa, Ángeles A1 Tepes, Bojan A1 Keco-Huerga, Alma A1 Bujanda, Luis A1 Lucendo, Alfredo J A1 Rodrigo, Luis A1 Vaira, Dino A1 Fernández-Salazar, Luis A1 Huguet, Jose M A1 Pérez-Lasala, Jorge A1 Jurecic, Natasa Brglez A1 Fadeenko, Galina A1 Barrio, Jesús A1 Areia, Miguel A1 Ortuño, Juan A1 Pellicano, Rinaldo A1 Leja, Marcis A1 Molina-Infante, Javier A1 Bogomolov, Pavel A1 Alekseenko, Sergey A1 Domínguez-Cajal, Manuel A1 Gómez-Camarero, Judith A1 Ntouli, Vassiliki A1 Martínez-Domínguez, Samuel J A1 Ruiz-Zorrilla, Rafael A1 Núñez, Oscar A1 Sarsenbaeva, Aiman Silkanovna A1 Almela, Pedro A1 Phull, Perminder A1 Espada, Marta A1 Puig, Ignasi A1 Nyssen, Olga P A1 Mégraud, Francis A1 O'Morain, Colm A1 Gisbert, Javier P A1 the Hp-EuReg Investigators, K1 Helicobacter pylori K1 statins K1 treatment AB Statins could increase the effectiveness of Helicobacter pylori eradication therapies due to their anti-inflammatory effect. The aim of this study was to analyze the impact of this therapeutic association in real life. This is a multicenter, prospective, non-interventional study aimed at evaluating the management of H. pylori by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap from 2013 to 2020. The association between statin use and H. pylori eradication effectiveness was evaluated through multivariate analysis. Overall, 9988 and 705 patients received empirical and culture-guided treatment, respectively. Overall, statin use was associated with higher effectiveness in the empirical group (OR = 1.3; 95%CI = 1.1-1.5), but no association was found with first-line treatment effectiveness (N = 7738); as an exception, statin use was specifically associated with lower effectiveness of standard triple therapy (OR = 0.76; 95%CI = 0.59-0.99). In the rescue therapy empirical group (N = 2228), statins were associated with higher overall effectiveness (OR = 1.9; 95%CI = 1.4-2.6). However, sub-analyses by treatment schemes only confirmed this association for the single-capsule bismuth quadruple therapy (OR = 2.8; 95%CI = 1.3-5.7). No consistent association was found between statin use and H. pylori therapy effectiveness. Therefore, the addition of statins to the usual H. pylori treatment cannot be currently recommended to improve cure rates. SN 2079-6382 YR 2021 FD 2021-08-11 LK http://hdl.handle.net/10668/18414 UL http://hdl.handle.net/10668/18414 LA en DS RISalud RD Feb 18, 2025